R&D spending rises from KRW 6.1 billion to KRW 20.7 billion
Zacubo monthly prescription value tops KRW 10 billion for first time in October
"Virtuous cycle of reinvesting new drug revenue in R&D"]

Onconic Therapeutics maintained a cumulative profit through the first nine months of the year while significantly increasing its research and development (R&D) investment in new drug development.


Onconic Therapeutics said on November 16 that it recorded cumulative revenue of KRW 64.4 billion and operating profit of KRW 3 billion through the third quarter. Revenue rose 70.3% year on year, while operating profit fell 72.7%.

A view of Onconic Therapeutics' research center. Onconic Therapeutics

A view of Onconic Therapeutics' research center. Onconic Therapeutics

View original image

Third-quarter revenue came to KRW 17 billion, affected by lower production due to the summer vacation period and other factors. The company posted an operating loss of KRW 4.3 billion, reflecting higher R&D expenses from research into new pipelines and expanded domestic and overseas clinical trials. Its net loss totaled KRW 7.7 billion, including non-cash foreign currency translation losses arising from sharp exchange rate fluctuations in the dollar-denominated assets it holds.


Cumulative R&D expenses through the third quarter rose about 3.4-fold, from KRW 6.1 billion to KRW 20.7 billion. The company said, "Maintaining a cumulative operating profit while making large-scale investments in new drug development demonstrates our differentiated business structure: securing revenue through the commercialization of our own new drugs and reinvesting it in the development of subsequent drugs."


R&D spending in the third quarter reached KRW 10.1 billion, close to the approximately KRW 10.5 billion spent throughout the first half of the year. The company said investments were made in areas including ▲new research on OCN-501 ▲Phase 3 trials to secure additional indications for Zacubo ▲clinical development of the anticancer drug Nesuparib for four types of cancer ▲preliminary consultations with the U.S. Food and Drug Administration (FDA) ahead of entering U.S. clinical trials ▲preparations to manufacture medicines for global clinical trials in compliance with cGMP standards.


Domestic prescriptions of Zacubo, Korea's 37th domestically developed new drug, have also continued to grow rapidly. According to UBIST, a pharmaceutical market research firm, the value of prescriptions filled outside hospitals reached approximately KRW 28.75 billion in the third quarter, up 109.6% year on year. In October, monthly prescription value exceeded KRW 10 billion for the first time, reaching approximately KRW 10.27 billion.



An Onconic Therapeutics official said, "Building on our virtuous-cycle growth model of reinvesting revenue from the commercialization of our first new drug in the development of subsequent drugs, we will further expand global clinical development of new pipelines and overseas market entry next year."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing